PharmAbcine to Present Preclinical Data of Blood Vessel Stabilizing PMC-402 at 2020 AACR Meeting

Daejeon, Korea, May 19, 2020 - PharmAbcine Inc. (KOSDAQ: 208340) announced today that it will present preclinical data of PMC-402, an active vessel stabilizing monoclonal antibody, at the 2020 American Association for Cancer Research (AACR).  The meeting will be held on June. 22nd – June. 24th. All poster presentations will be made available online on the first day of the meeting.

PMC-402 is a next generation therapeutic antibody that regulates the formation of functional blood vessels.  It is expected to induce normalization of leaky blood vessels formed around tumor mass in a ligand-independent manner. It has demonstrated its anti-tumor effect in a mouse model for colon cancer, corroborated by the improvement in immune cell infiltration and delivery of anti-cancer agents to a tumor site when administered as a single agent or as a combination therapy regimen.

The presentation will include the unique molecular mechanism of the vessel stabilizer and its anti-tumor activity, supported by preclinical data including changes in capillary formation, improvement of hypoxic condition in TME, and increased numbers of TILs (Tumor-Infiltrating Lymphocytes) upon treatment. The highlight of the presentation will be the anti-tumor effects observed in a mouse model for colon cancer following the treatment of a single agent or combination with anti-PD1 antibody. Due to its lack of cross activity against mouse Tie2, PharmAbcine developed and used PMC-403, a surrogate of PMC-402.

Poster presentation details:

  • Title: A novel anti-Tie2 antibody stabilized vessel and increased tumor infiltrated lymphocyte
  • Session Category: Angiogenesis and Vascular Normalization in Tumor Immunity and Treatment Response
  • Session Date and Time: Monday June 22nd , 2020
  • Location: Annual Virtual Meeting II
  • Permanent Abstract Number: 1483

According to Dr. Jin-San Yoo, CEO pf PharmAbcine, PMC-402 could be beneficial to treat patients with AMD (Age-related Macular Degeneration), DR, Sepsis as well as ARDS (Acute Respiratory Distress Syndrome), one of the main complications of COVID-19 patients. PharmAbcine plans to initiate IND enabling studies this year and submit IND in 2021.

About PharmAbcine Inc.

PharmAbcine is a clinical-stage biotech company focusing on developing fully human antibody (mAb) therapeutics, including especially next-generation multi-specific antibodies. The company has achieved multi-specific antibody technology through its in-house novel technology called DIG-Body, PIG-Body and TIG-Body. Using innovative discovery technology together with excellent human resources, it provides superlative immunotherapeutic for indications in immuno-oncology, immunology and ophthalmology.

PharmAbcine has its own HuPhage library and innovative selection system. PharmAbcine’s advanced 3G expression system accommodates high levels of antibody production with high reproducibility. With our highly advanced technology platforms, we provide high-quality antibody generation services. Our high standards have allowed us to expand co-development opportunities with not only existing but also potential partners.

Under the collaboration with SAMSUNG MEDICAL CENTER, we have over 300 patients-derived cancer stem cell libraries and an animal model system to evaluate internal pipeline development.

Additional information about PharmAbcine can be found on our website at http://www.pharmabcine.com.

Contacts

Yohan Jung

82-42-863-2017

yohan.jung@pharmabcine.com

Back to news